GenSpera Receives Patent on Targeted Prostate Cancer Drugs
6/6/2013 9:53:54 AM
More...
|
GenSpera Chief Executive Officer Craig Dionne to Present to Biotechnology Industry Organization (BIO) Business Forum™ on April 23, 2013 in Chicago
4/10/2013 6:35:32 AM
More...
|
GenSpera Announces First Patient Treated in G-202 Phase II Hepatocellular Carcinoma Tria
2/21/2013 9:23:22 AM
More...
|
Interim Data on GenSpera’s G-202 Presented at Symposium on Molecular Targets and Cancer Therapeutics
11/9/2012 11:05:32 AM
More...
|
GenSpera and the Statewide Clinical Trials Network of Texas to Conduct Phase II Study of G-202 in Patients With Hepatocellular Carcinoma
10/25/2012 9:55:44 AM
More...
|
GenSpera Obtains Authorization for G-202 Phase II Trial in the United Kingdom
9/4/2012 9:59:00 AM
More...
|
GenSpera Appoints Nancy Jean Barnabei VP Finance and Treasurer
8/21/2012 9:55:32 AM
More...
|
GenSpera Cleared to Initiate Phase II G-202 Trial in Prostate Cancer
7/31/2012 10:04:21 AM
More...
|
GenSpera G-202 Data in Peer-Reviewed Journal Supports Prodrug Strategy
6/28/2012 9:46:41 AM
More...
|
GenSpera Appoints Dr. Peter E. Grebow to Its Board of Directors
5/31/2012 10:13:40 AM
More...
|
|